Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Avery Williamson

Physician Assistant Williamsport, PA Physician Assistant

NPI 1821548140 CMS profile 11212257

145 Shaffer St, Williamsport, PA 17702

Open in the dashboard

General payments

$5,134

314 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Avery Williamson of Williamsport, PA is reported in the CMS Open Payments database as having received $5,134 across 314 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,982 119
2024 General $1,310 81
2023 General $1,487 94
2022 General $338 19
2021 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Avery Williamson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Avery Williamson were reported at $1,982. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Avery Williamson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $17 $132 $37–$438 $132
2022 $338 $155 $48–$522 $149
2023 $1,487 $167 $52–$557 $160
2024 $1,310 $178 $55–$600 $164
2025 $1,982 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,196 65 payments
  2. Lilly USA, LLC $721 51 payments
  3. Novo Nordisk Inc $674 43 payments
  4. Pfizer Inc. $489 38 payments
  5. GlaxoSmithKline, LLC. $269 16 payments
  6. AstraZeneca Pharmaceuticals LP $264 13 payments
  7. Amgen Inc. $223 15 payments
  8. Astellas Pharma US Inc $197 14 payments
  9. Exact Sciences Corporation $194 8 payments
  10. Dexcom, Inc. $180 9 payments
  11. Other $727 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,134 314 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $544 23 payments
  2. Ozempic $506 31 payments
  3. UBRELVY $446 21 payments
  4. MOUNJARO $435 33 payments
  5. NURTEC ODT $402 31 payments
  6. RYBELSUS $369 24 payments
  7. JARDIANCE $286 18 payments
  8. VRAYLAR Neuroscience $241 20 payments
  9. VRAYLAR Neuroscience $236 14 payments
  10. ZAVZPRET $225 16 payments
  11. Other $3,240 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

3,891

Median for Physician Assistant: 241

Drug cost

$249,148

Median for Physician Assistant: $4,110

Branded share of claims

16.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 53 $54,570
Jardiance Empagliflozin Brand 30 $49,938
Ozempic Semaglutide Brand 30 $31,758
Farxiga Dapagliflozin Propanediol Brand 28 $26,986
Xarelto Rivaroxaban Brand 17 $16,170
Trulicity Dulaglutide Brand 15 $14,314
Fenofibrate Generic 13 $7,690
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 13 $5,902
Metoprolol Succinate Generic 190 $2,707
Atorvastatin Calcium Generic 191 $2,118

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$49,369

Of which drugs: $25,435

Medicare patients

142

Average age 74

Services billed

1,533

100 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Osteoporosis 29%
Depression 27%
Diabetes 24%
Ischemic heart disease 17%
COPD 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 15 900 $19,337
Vaccine for influenza for injection into muscle 90662 Office 49 49 $4,009

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $135
$135 — —
QULIPTA
  • AbbVie, Inc. $116
$116 — —
JARDIANCE
  • Lilly USA, LLC $102
$102 30 —
MOUNJARO
  • Lilly USA, LLC $88
$88 — —
VRAYLAR
  • AbbVie, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

314 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record